Go Pro

Cookson Peirce & Co. Inc. Invests $1.39 Million in Indivior PLC $INDV

Indivior logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Cookson Peirce & Co. purchased 33,886 Indivior shares worth approximately $1.39 million in the second quarter. Institutional investors collectively own 60.33% of the company, with several major firms increasing their positions.
  • Analyst sentiment remains favorable, with five Buy ratings and two Holds, producing a “Moderate Buy” consensus and an average price target of $45.17. Barclays maintains an Overweight rating despite reducing its target to $43.
  • Indivior shares opened at $34.87, below their 50-day moving average of $39.33, while the company reported $343 million in quarterly revenue and $5.75 in earnings per share. A CFO share sale and chief accounting officer purchase were also disclosed.
  • MarketBeat previews the top five stocks to own by September 1st.

Cookson Peirce & Co. Inc. bought a new position in shares of Indivior PLC (NASDAQ:INDV - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 33,886 shares of the company's stock, valued at approximately $1,390,000.

Other large investors have also recently bought and sold shares of the company. Goldman Sachs Group Inc. increased its position in shares of Indivior by 18.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 8,368,996 shares of the company's stock worth $79,757,000 after purchasing an additional 1,299,425 shares in the last quarter. Fuller & Thaler Asset Management Inc. grew its stake in Indivior by 101.0% during the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 6,371,534 shares of the company's stock worth $228,611,000 after buying an additional 3,201,639 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Indivior by 57.9% during the fourth quarter. Vanguard Group Inc. now owns 5,473,891 shares of the company's stock worth $196,403,000 after buying an additional 2,008,078 shares in the last quarter. State Street Corp raised its stake in shares of Indivior by 65.5% in the fourth quarter. State Street Corp now owns 4,659,281 shares of the company's stock valued at $167,175,000 after acquiring an additional 1,844,532 shares during the last quarter. Finally, Rubric Capital Management LP raised its stake in shares of Indivior by 31.6% in the second quarter. Rubric Capital Management LP now owns 4,647,179 shares of the company's stock valued at $68,499,000 after acquiring an additional 1,117,140 shares during the last quarter. 60.33% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

INDV has been the topic of a number of research analyst reports. Zacks Research lowered Indivior from a "strong-buy" rating to a "hold" rating in a research report on Monday, June 29th. Craig Hallum reiterated a "buy" rating and issued a $53.00 price objective on shares of Indivior in a research report on Tuesday, August 4th. Weiss Ratings lowered Indivior from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Friday, August 21st. Finally, Barclays decreased their target price on Indivior from $46.00 to $43.00 and set an "overweight" rating on the stock in a report on Wednesday, August 5th. Five analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $45.17.

Check Out Our Latest Analysis on INDV

Indivior Price Performance

Shares of INDV opened at $34.87 on Monday. The stock's fifty day simple moving average is $39.33 and its 200-day simple moving average is $36.01. The firm has a market capitalization of $4.12 billion, a PE ratio of 12.50 and a beta of 0.86. Indivior PLC has a 12-month low of $22.22 and a 12-month high of $42.81.

Indivior (NASDAQ:INDV - Get Free Report) last announced its quarterly earnings data on Tuesday, June 30th. The company reported $5.75 EPS for the quarter. The firm had revenue of $343.00 million during the quarter. Indivior had a negative return on equity of 283.11% and a net margin of 26.65%. Analysts anticipate that Indivior PLC will post 3.66 EPS for the current year.

Insider Transactions at Indivior

In other Indivior news, CFO Ryan Preblick sold 36,000 shares of the firm's stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $37.70, for a total value of $1,357,200.00. Following the transaction, the chief financial officer directly owned 284,751 shares of the company's stock, valued at approximately $10,735,112.70. This trade represents a 11.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Woodrow D. Anderson bought 1,500 shares of the stock in a transaction on Thursday, August 27th. The shares were acquired at an average cost of $35.69 per share, with a total value of $53,535.00. Following the acquisition, the chief accounting officer directly owned 27,638 shares in the company, valued at approximately $986,400.22. This trade represents a 5.74% increase in their position. The disclosure for this purchase is available in the SEC filing. 0.74% of the stock is owned by corporate insiders.

Indivior Company Profile

(Free Report)

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company's portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.

See Also

Want to see what other hedge funds are holding INDV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Indivior PLC (NASDAQ:INDV - Free Report).

Institutional Ownership by Quarter for Indivior (NASDAQ:INDV)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Should You Invest $1,000 in Indivior Right Now?

Before you consider Indivior, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Indivior wasn't on the list.

While Indivior currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines